Gastric adenocarcinoma and gastrointestinal stromal tumour arise in the same organ but represent entirely distinct diseases. Separate cellular origins, separate molecular drivers, separate treatment protocols. Chemotherapy that works for stomach cancer has no activity in GIST. Imatinib that works for GIST has no role in gastric adenocarcinoma. The pathology report determines which treatment the patient receives, and getting that wrong has direct clinical consequences.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “GIST and gastric adenocarcinoma are two separate malignancies arising in the same anatomical location. Immunohistochemistry must confirm the diagnosis before any systemic treatment decision is made. Applying gastric chemotherapy to a GIST produces no response. The pathology drives everything here and it cannot be assumed.”

The distinction runs across cellular origin, molecular biology, surgical scope and systemic treatment response.

• Cellular origin: Gastric adenocarcinoma arises from the glandular epithelium of the mucosal lining. GIST arises from the interstitial cells of Cajal within the muscle wall. Different cell. Entirely different tumour biology.
• Molecular driver: Gastric cancer is driven by H. pylori, HER2 amplification and chromosomal instability. GIST is driven by KIT or PDGFRA tyrosine kinase mutations in over 85 percent of cases — that targetable mutation is what makes imatinib work. Gastric cancer has nothing equivalent.
• Lymph node involvement: Gastric adenocarcinoma spreads to regional lymph nodes consistently, making D2 lymphadenectomy standard. GIST rarely involves lymph nodes at all. Dissecting them in a GIST resection adds morbidity with no oncological return.
• Chemotherapy response: FLOT, FOLFOX and DCF are active in gastric adenocarcinoma. GIST is chemoresistant. Standard cytotoxic chemotherapy has no meaningful activity in GIST and should not be used.

For patients with either diagnosis requiring minimally invasive surgical resection, robotic cancer surgery enables precise D2 lymphadenectomy for stomach cancer and margin-negative wedge resection for GIST.

• Surgical scope differs significantly: Gastric cancer needs D2 lymph node clearance because nodal metastasis determines both staging and prognosis. GIST needs only a clear surgical margin. Adding lymphadenectomy to a GIST resection is unnecessary and harmful.
• Imatinib works only in GIST: It blocks the mutant KIT or PDGFRA driving tumour proliferation. High-risk GIST patients take it for three years after surgery and advanced disease responds in over 80 percent of cases. In gastric adenocarcinoma it has no role whatsoever.
• HER2 is gastric cancer territory: Around 15 to 20 percent of gastric adenocarcinomas overexpress HER2, qualifying those patients for trastuzumab alongside chemotherapy. In GIST, HER2 testing carries no clinical relevance.
• Both can occur together: GIST and gastric adenocarcinoma can present simultaneously in the same patient. Each needs independent pathological confirmation and its own treatment plan even when a single surgical operation addresses both.

For patients wanting to recognise early clinical warning signs that prompt the endoscopic investigations identifying these tumours, our blog on stomach cancer warning signs covers the symptom profile in clinical detail.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He has published clinical research on GIST and imatinib in locally advanced cases in Indian patients, performs robotic gastrectomy with D2 lymphadenectomy for gastric adenocarcinoma and margin-negative wedge resection for GIST, and presents every upper gastrointestinal tumour to the tumour board before treatment planning begins.

Misclassifying GIST as gastric adenocarcinoma is not a documentation error — it is a treatment error. Whether the patient receives imatinib or FLOT depends entirely on immunohistochemistry including CD117, DOG1 and HER2, and that distinction is confirmed at the first consultation at MACS Clinic. Call +91 8104310753 to book your consultation.

References:

1. National Institutes of Health — Imatinib Treatment for Gastrointestinal Stromal Tumour: https://pmc.ncbi.nlm.nih.gov/articles/PMC3837608/
2. PubMed Central — 2023 GEIS Guidelines for Gastrointestinal Stromal Tumors: https://pmc.ncbi.nlm.nih.gov/articles/PMC10467260/

Disclaimer: This blog is intended for educational and informational purposes only and does not substitute professional medical advice, diagnosis or treatment.

Colorectal cancer has traditionally been considered a disease of people above 50. That picture is changing. Indian data from tertiary cancer centres shows a rising proportion of cases in patients under 40. Some studies put that figure at 10 to 15 percent. In Western registries it’s under 5. The shift is real, the drivers are known, and the delay in diagnosis is the part that’s doing the most damage.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “I see young patients with colorectal cancer regularly now. People in their 30s who spent six months being told it was acidity or piles before anyone did a colonoscopy. The biology in young Indian patients is often more aggressive too, higher grade, more mucinous, presenting at a later stage simply because no one thought to investigate early. That has to change.”

The causes aren’t mysterious. They’re sitting on every dinner table and in every office chair.

• Ultra-processed food and low fibre intake: Traditional Indian diets carried fibre from lentils, vegetables and whole grains. Urban diets swapped that out for packaged, processed and fast food. Less fibre means slower bowel transit. Slower transit means longer carcinogen contact with the colonic wall. That’s the mechanism. It’s not complicated.
• Sedentary lifestyle and obesity: Central obesity and physical inactivity both raise colorectal cancer risk on their own. Put them together in a desk-bound 35-year-old with a rising BMI and the risk compounds. Indian urban data tracks this exactly.
• Smoking and alcohol: Independent risk factors, both. Rates among Indian men under 40 have climbed. Cancer biology in smokers runs more aggressive. Presentation tends to be later stage. Two bad combinations in one.
• Genetic factors underdiagnosed: Lynch syndrome and familial adenomatous polyposis drive early-onset colorectal cancer. Both run in families. Most young Indian patients never get tested. The hereditary proportion of early-onset cases is significant. Finding it changes the surgical plan. It also means siblings and children carry the same risk and need to know.

For patients at high risk who need surgical treatment, robotic cancer surgery delivers precision colorectal resection with faster recovery than open surgery.

The gap is not information. It’s action.

• Don’t dismiss rectal bleeding: In India, bleeding is almost automatically called piles. Piles are common. Cancer is not rare either. A colonoscopy takes 30 minutes. When bleeding persists, that 30 minutes is not optional.
• Screen earlier with family history: Average risk? Start at 40. First-degree relative with colorectal cancer? Start at 40 or 10 years before their diagnosis age, whichever comes first. That rule exists because hereditary colorectal cancer runs ahead of the standard screening age.
• Lynch syndrome warrants genetic counselling: Colorectal cancer under 50 combined with family history of bowel, uterine or ovarian cancer. That pattern needs a genetics referral. Finding Lynch syndrome changes surgical planning. More importantly, it tells siblings and children they’re at risk before they get sick.
• Change the diet before symptoms appear: More fibre. Less processed meat. Less red meat. Move more. Stay in a healthy weight range. None of this eliminates risk completely. But it shifts the odds, and starting at 30 shifts them more than starting at 50.

For a practical breakdown of what early colorectal symptoms actually look like and when they need investigation, our blog on early detection rectal cancer covers the warning signs in detail.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs robotic and laparoscopic colorectal cancer surgery including intersphincteric resection for low rectal cancers, integrates genetic risk assessment into the young patient consultation, and presents every colorectal cancer case to the tumour board before the surgical plan is confirmed.

Young patients with colorectal cancer deserve surgical precision, but they also deserve a conversation about genetic risk, fertility implications of pelvic surgery and long-term quality of life. That conversation happens at MACS Clinic before the operation, not after it. Call +91 8104310753 to book your consultation.

References:

1. National Institutes of Health — The Increase of Early-Onset Colorectal Cancer: https://pmc.ncbi.nlm.nih.gov/articles/PMC12966572/
2. PubMed Central — Focusing on Colorectal Cancer in Young Adults (Review): https://pmc.ncbi.nlm.nih.gov/articles/PMC10729308/

Disclaimer: This content is for general awareness about the rising incidence of colorectal cancer in younger adults. It is not a substitute for a clinical consultation, colonoscopy recommendation or personalised cancer screening advice. If you or a family member have symptoms or a family history of colorectal cancer, consult a surgical oncologist for a proper evaluation.

Only 15 to 20 percent of pancreatic cancer patients qualify for Whipple surgery. The rest have disease that has spread too far or involves blood vessels that make surgery unsafe. Candidacy comes down to three things: where the tumour sits, whether it has grown into major vessels, and whether the patient is fit enough for one of the most demanding operations in oncology.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Whipple surgery is the only operation that offers a realistic chance of cure in pancreatic cancer. But it only works when the cancer is truly resectable, meaning it hasn’t wrapped around the superior mesenteric artery or vein in a way that makes clear margins impossible. The staging assessment before the operation is as important as the operation itself. Getting that wrong in either direction, operating when you shouldn’t or not operating when you should, changes outcomes dramatically.”

Four criteria define resectability. All four need to be met.

• Cancer in the head of the pancreas: The Whipple procedure removes the head of the pancreas, the duodenum, part of the bile duct, the gallbladder and nearby lymph nodes. It’s the right operation for cancers in the pancreatic head. Body and tail cancers need distal pancreatectomy, not Whipple.
• No involvement of major vessels: The superior mesenteric artery and superior mesenteric vein run directly behind the pancreatic head. Cancer that has encased the artery makes clear margins impossible. Abutment alone may still be resectable. Encasement is not.
• No distant metastasis: Liver metastases, peritoneal spread or lung involvement make Whipple palliative at best. Staging CT and PET-CT must confirm disease is localised before the operation is planned.
• Patient fitness: Whipple is a six to eight hour operation with significant physiological demand. Cardiac reserve, lung function, nutritional status and performance score all feed into the fitness assessment. An unfit patient with a resectable tumour may not be a surgical candidate until fitness improves.

For patients whose pancreatic cancer requires minimally invasive surgical removal, robotic cancer surgery includes robotic pancreaticoduodenectomy, available at select high-volume centres with surgeons trained in robotic pancreatic surgery.

Not all unresectable presentations are permanently unresectable.

• Borderline resectable: The tumour abuts but hasn’t encased the superior mesenteric vessels. Surgery is technically possible but margins are at risk. Neoadjuvant chemotherapy, typically FOLFIRINOX or gemcitabine-nab paclitaxel, is given first to shrink the tumour away from the vessels before re-staging.
• Response-guided restaging: After 4 to 6 months of neoadjuvant chemotherapy, CT and sometimes PET-CT reassess whether vessel clearance has improved. Patients who downstage to clearly resectable territory can proceed to Whipple. Not all do.
• Locally advanced but not metastatic: Cancer that has grown significantly into the SMA or coeliac axis. Technically unresectable in most cases. Systemic chemotherapy and sometimes radiation are used. A small proportion downstage enough to revisit surgery.
• Palliative surgery for symptoms: Patients who aren’t Whipple candidates can still have biliary bypass or gastric bypass surgery to relieve jaundice or gastric outlet obstruction without removing the tumour.

For patients with pancreatic cancer where Whipple isn’t possible, our blog on pancreatic cancer survival explains what the outlook looks like across stages and treatment types.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He is among the very few surgeons in India performing robotic Whipple surgery, assesses every pancreatic cancer case at the tumour board before confirming resectability, and coordinates neoadjuvant chemotherapy planning for borderline resectable cases with the medical oncology team.

Whipple surgery is one of the hardest operations to do well. Surgical volume, anatomical familiarity with the pancreatic head and its vascular relationships, and the team behind the surgeon all determine whether a technically demanding resection ends with clear margins and a patient who recovers. That’s the gap between a centre that does this occasionally and one that does it at real volume. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

In oral cancer surgery, neck dissection is part of the same operation in most cases, not a separate procedure. Oral cancers spread to the neck lymph nodes early, often before anything is visible or palpable. Waiting until nodes are clinically positive before clearing them is a risk the evidence doesn’t support. For most tumours at stage T2 and above, and for many T1 tumours with depth of invasion above 4mm, neck dissection happens at the same time as the primary surgery.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Neck dissection with oral cancer surgery is not a question of whether but when and how much. Oral cancers use the lymphatic pathways to the neck before they announce themselves clinically. Waiting for nodes to appear before addressing them is too late in most cases. The decision about which levels to clear and whether both sides need addressing is made at the tumour board, not in the operating room.”

Stage, depth and clinical status all feed into the decision.

• Elective neck dissection: Done when the neck appears clinically clear on examination and imaging but the tumour’s depth of invasion, size or location puts the risk of occult nodal spread above 15 to 20 percent. That threshold is based on the landmark D’Cruz NEJM trial. Levels I to III are cleared as standard.
• Therapeutic neck dissection: Done when nodes are already clinically positive on examination, CT or PET-CT. More extensive. Usually includes levels I to IV, sometimes V depending on which nodes are involved and where.
• Depth of invasion trigger: Tumours with depth of invasion above 4mm carry enough risk of occult nodal spread that elective neck dissection is standard even in early stage oral cancers where the neck appears clear. Depth measured on MRI or post-resection pathology.
• Contralateral neck: Midline tumours, tongue cancers crossing the midline and floor of mouth cancers often spread to both sides of the neck. Bilateral neck dissection is performed in the same operation when staging and tumour location indicate it.

For patients choosing minimally invasive surgery for the neck component of oral cancer treatment, robotic cancer surgery includes the MIND technique, a robotic infraclavicular approach to neck dissection that avoids any visible scar on the neck.

Structured, level-by-level lymph node clearance. Not blind excision.

• Levels cleared: The neck is divided into levels I to V. Oral cancer most commonly spreads to levels I, II and III. These are removed in every elective neck dissection. Levels IV and V are added when clinical findings or frozen section dictates.
• Structures preserved: The spinal accessory nerve controlling shoulder movement, the internal jugular vein and the sternocleidomastoid muscle are preserved unless cancer has directly invaded them. Unnecessary sacrifice causes function loss the patient didn’t need.
• Same operation as primary: Neck dissection happens simultaneously with oral cavity resection in almost every case. Two separate operations and two recoveries when one achieves both is not how experienced surgical oncology teams work.
• Frozen section intraoperatively: Suspicious nodes are sent for frozen section during the operation. Positive findings can prompt extension of the dissection to additional levels before the patient leaves theatre.

For a complete explanation of what neck dissection surgery involves and what recovery looks like, our blog on neck dissection surgery covers the full procedure in detail.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs oral cancer resection with integrated neck dissection, MIND robotic infraclavicular neck dissection for patients wanting no neck scar, and TORS for accessible oropharyngeal tumours, with every case reviewed by the tumour board before the surgical plan is confirmed.

The decision about levels, bilaterality and surgical approach in neck dissection is built on volume. Surgeons who do this every week read the anatomy differently from surgeons who do it occasionally, and that difference shows in recurrence rates and functional outcomes. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Head and neck cancer can recur after robotic surgery, including TORS. The risk depends heavily on the original stage, whether margins were clear, HPV status and whether lymph nodes were involved. HPV-positive oropharyngeal cancers have significantly lower recurrence rates than HPV-negative disease. Most recurrences appear within the first two years. After five years without disease, the risk drops sharply.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Head and neck cancer recurrence after TORS is real, but the numbers are more encouraging than most patients expect, especially for HPV-positive disease. The surveillance schedule isn’t optional, it’s what catches recurrence early enough to treat it. A recurrence found at three months on clinical examination is a very different situation from one found a year later when the patient stopped coming for follow up.”

Stage, margins, biology and nodal status. All four feed into the risk.

• Surgical margin status: Clear margins after TORS significantly reduce local recurrence risk. Close or positive margins raise it. Some patients need adjuvant radiation to the primary site specifically because of margin findings on pathology.
• Lymph node involvement: Positive nodes at surgery mean higher risk of regional and distant recurrence. Neck dissection, performed alongside or after TORS, addresses regional nodes. Positive nodes usually trigger adjuvant radiation or chemoradiation.
• HPV status: HPV-positive oropharyngeal cancer, base of tongue and tonsil, has consistently better outcomes than HPV-negative disease. Three-year recurrence rates for HPV-positive TORS patients in published series sit below 15 percent. HPV-negative disease is more aggressive and recurs more often.
• Stage at surgery: Stage I and II disease treated with TORS alone has low recurrence rates. Stage III and IV disease with nodal involvement needs adjuvant treatment and carries a higher long-term recurrence risk even when surgery is successful.

For patients whose recurrence workup or salvage plan involves further minimally invasive surgery, robotic cancer surgery remains an option for selected recurrences in anatomically accessible sites.

Structured surveillance. Not passive monitoring.

• Clinical examination schedule: Every 6 to 8 weeks in the first year, every 3 months in year two, then less frequently. The surgeon examines the primary site, neck and oral cavity at every visit. This is when most recurrences are found first.
• Nasendoscopy: Flexible scope examination of the primary site including base of tongue, tonsil, pharynx and larynx. Allows direct visualisation of areas not visible on external examination. Done at each follow up.
• PET-CT imaging: At 3 to 6 months post-treatment to confirm complete response. Repeated if symptoms develop or examination raises concern. The most sensitive tool for detecting occult regional or distant recurrence.
• Salvage options: Local recurrence after TORS can sometimes be re-resected robotically. Regional neck recurrence may be salvage dissected. Distant metastases are managed with systemic treatment. Early detection is what keeps salvage surgery on the table.

For patients wanting to understand what TORS involves and what the procedure itself achieves, our blog on TORS surgery covers the full picture.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs TORS for oropharyngeal and base of tongue cancers, MIND neck dissection, and RABIT thyroid surgery, integrating recurrence surveillance into the post-surgical plan from the first consultation so patients understand the follow up commitment before they leave theatre.

High-volume TORS surgery means the margin decisions, neck dissection planning and adjuvant therapy discussions happen with a surgeon who reads this anatomy every week, not occasionally. That familiarity is what separates a good outcome from a preventable recurrence. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.